• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

FluoGuide

37.00 SEK-1.86 %10.7. klo 18.29
Less than 1K followers

FLUO

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-1.86 %
-19.91 %
+3.35 %
+5.71 %
+7.87 %
-9.98 %
-54.88 %
-62.85 %
+312.70 %

FluoGuide is a Danish company operating in the medical technology sector. The company's business focus is on research and development of treatments for various forms of cancer, with the greatest focus on the development of products that guide surgical procedures. The products bind to cancer cells, which then light up and are intended to be used to precisely remove harmful tumors in the patient's tissue.

Read more
Market cap
604.92M SEK
Turnover
115.12K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Webcasts
Press releases
ShowingAll content types

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
25.8.
2026

Interim report Q2'26

26.11.
2026

Interim report Q3'26

Press release01.07.2026 klo 09.36

Update on 2026 Outlook and Company progress

FluoGuide
Press release30.06.2026 klo 11.00

Redeye: FluoGuide: First part of Phase 2 HNC trial clears dose-finding phase

FluoGuide
Press release29.06.2026 klo 11.32

FluoGuide announces positive results from Phase 2 oral head and neck cancer trial

FluoGuide

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release28.05.2026 klo 19.35

Redeye: FluoGuide (Q1 Review): Catalyst-Heavy Remainder of 2026

FluoGuide
Regulatory press release27.05.2026 klo 08.09

FluoGuide A/S publishes interim report for Q1 2026

FluoGuide
Press release13.05.2026 klo 17.45

Invitation to brain surgery simulation

FluoGuide
Press release13.05.2026 klo 16.17

Invitation to FluoGuide A/S live webcast on 27 May 2026

FluoGuide
Press release14.04.2026 klo 14.33

Redeye: Fluoguide: Interview with CEO Morten Albrechtsen

FluoGuide
Press release10.04.2026 klo 09.30

Positive interim results from an investigator-initiated study of FG001 in meningioma and low-grade glioma surgery, re-presented at SNOG

FluoGuide
Press release07.04.2026 klo 09.53

Redeye: FluoGuide: Shining light on a mispriced opportunity

FluoGuide
Regulatory press release25.03.2026 klo 18.44

Minutes from Annual General Meeting in FluoGuide A/S

FluoGuide
Press release20.03.2026 klo 09.43

BioStock: FluoGuide receives FDA Fast Track designation for FG001 in high-grade glioma

FluoGuide
Regulatory press release18.03.2026 klo 22.19

FluoGuide receives FDA Fast Track Designation for FG001 in high-grade glioma

FluoGuide
Regulatory press release10.03.2026 klo 18.50

Notice of Annual General Meeting in FluoGuide A/S

FluoGuide
Press release26.02.2026 klo 10.45

Redeye: Fluoguide (Q4 Initial take): Key milestones to drive value in 2026

FluoGuide
Press release25.02.2026 klo 17.33

BioStock: FluoGuide comments on the annual report and road ahead

FluoGuide
Regulatory press release25.02.2026 klo 08.09

FluoGuide A/S publishes annual report for the fiscal year 2025

FluoGuide
Regulatory press release25.02.2026 klo 08.07

FluoGuide A/S publishes interim report for Q4 2025

FluoGuide
Regulatory press release20.02.2026 klo 21.40

FDA clears FluoGuide’s IND for FG001 in High-Grade Glioma; U.S. clinical trial remains on track

FluoGuide
Press release19.02.2026 klo 10.16

Invitation to FluoGuide A/S (Nasdaq: FLUO) live webcast on 25 February 2026

FluoGuide